<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dalamaga, Maria</style></author><author><style face="normal" font="default" size="100%">Polyzos, Stergios A</style></author><author><style face="normal" font="default" size="100%">Karmaniolas, Konstantinos</style></author><author><style face="normal" font="default" size="100%">Chamberland, John</style></author><author><style face="normal" font="default" size="100%">Lekka, Antigoni</style></author><author><style face="normal" font="default" size="100%">Migdalis, Ilias</style></author><author><style face="normal" font="default" size="100%">Papadavid, Evangelia</style></author><author><style face="normal" font="default" size="100%">Dionyssiou-Asteriou, Amalia</style></author><author><style face="normal" font="default" size="100%">Mantzoros, Christos S</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Circulating fetuin-A in patients with pancreatic cancer: a hospital-based case-control study.</style></title><secondary-title><style face="normal" font="default" size="100%">Biomarkers</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Biomarkers</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">alpha-2-HS-Glycoprotein</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hospitals</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Pancreatic Neoplasms</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014 Dec</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">19</style></volume><pages><style face="normal" font="default" size="100%">660-6</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">CONTEXT: A proteomic analysis has proposed fetuin-A (alpha-2-HS-glycoprotein) as a new potential marker for pancreatic cancer (PC).

OBJECTIVE: Circulating fetuin-A levels in patients with PC.

METHODS: Serum fetuin-A was measured in 81 cases with PC and 81 matched controls before the initiation of any treatment.

RESULTS: Serum fetuin-A was not independently associated with the presence of PC. Although there was a trend with higher fetuin-A levels across PC stages, comparisons of fetuin-A in patients within different PC prognostic stages revealed no differences.

CONCLUSIONS: Circulating fetuin-A was similar between patients and controls and was not associated with the disease severity.</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/25347061?dopt=Abstract</style></custom1></record></records></xml>